Skip to content

Alpha-bisabolol for Onychomycosis Treatment

Alpha-bisabolol for Onychomycosis Treatment

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04940520
Enrollment
60
Registered
2021-06-25
Start date
2020-06-01
Completion date
2021-05-01
Last updated
2021-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Onychomycosis

Keywords

Onychomycosis, Phytotherapy, Laser Therapy, Plant Oils

Brief summary

Clinical, interventional, longitudinal study with random sampling. 60 patients will be divided into three groups, group A: control group, drug recommended by the Brazilian Society of Dermatology, group B: alpha bisabolol-based product associated with low-level laser therapy, and group C: alpha bisabolol based product. The topical application will be performed twice a day, while the laser application and photographs of the lesions, every 15 days. Areas of the lesions will be compared.

Detailed description

Introduction: Onychomycosis is an infection caused by fungi that feed on keratin, a protein that makes up most of the nails. In patients with diabetes mellitus and onychomycosis, the risk of foot complications is a concern, especially for those who do not perform the practice of self-care of the skin, nails and feet in general correctly, which can trigger an important tissue damage that culminates in limb amputation. One of the alternatives for the treatment are herbal medicines. The application of alpha-bisabolol in the pharmaceutical sector is related to its anti-inflammatory, antispasmodic, antiallergic, drug permeation and deworming properties, having an important action in the morphology of dermatophytic fungal cells. Objectives: Develop and evaluate a pharmaceutical formula with alpha-bisololol for the treatment of onychomycosis. Methods: Clinical, interventional, longitudinal study with random sampling. The study will be held at the Sthomatherapy Clinic of the Nursing Care and Teaching Center at the Samuel Libânio Hospital and at the DermatoCare Clinic Stomatherapy and Podiatry Clinic, Pouso Alegre, MG. 60 patients with onychomycosis will participate in this study, which will be divided into three groups, group A: control group, drug recommended by the Brazilian Society of Dermatology, group B: alpha bisabolol-based product associated with low-level laser therapy, and group C: alpha bisabolol based product. The topical application will be performed twice a day, while the laser application and photographs of the lesions, every 15 days.

Interventions

BIOLOGICALDrug recommended by the Brazilian Society of Dermatology

Using a drug recommended by the Brazilian Society of Dermatology, twice a day.

COMBINATION_PRODUCTAlpha bisabolol product and laser

Using alpha bisabolol-based product associated with low-level laser therapy. Alpha bisabolol-based product will be used twice a day, and laser therapy used once every fortnight.

BIOLOGICALAlpha bisabolol product

Using alpha bisabolol-based product twice a day

Sponsors

Universidade do Vale do Sapucai
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Volunteers with onychomycosis, * aged over 18 years.

Exclusion criteria

* Volunteers have a known allergic process to topical treatment, and those who present an allergic reaction to alpha bisabolol * patients with a history of neoplasm in a location close to the nail plate, and patients with psoriasis. * Volunteers who withdraw their consent at any time during the research, and those who present an allergic reaction to alpha bisabolol * Pregnant women.

Design outcomes

Primary

MeasureTime frameDescription
Injury area analysis2 monthsAll participants will have their nails photographed every 15 days for treatment control and evolution. Theses areas will be compared using the Image J program.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026